In Poland, a massive fundraising campaign led by a man known as Łatwogang has collected 280 million PLN to pay for a single gene therapy (Elevidys) for children with Duchenne muscular dystrophy. The drug costs $15 million per dose. The government says it can't afford to refund it, and the EMA hasn't even approved it yet.

At the exact same time, Paul Conyngham in Sydney – a tech entrepreneur with no biology background – used ChatGPT and AlphaFold to sequence his dog's tumor, design a personalized mRNA vaccine, and shrink the cancer by half. Total cost: $3,000.

The contrast is staggering. We're trapped in a system where we beg foreign pharma corporations for drugs they price into the stratosphere, while AI-powered personalized medicine is already here, cheap, and proving itself. Poland has thousands of brilliant researchers in bioinformatics, genetics, and immunology. Yet we spend billions on refunds for patented drugs instead of funding our own 10 interdisciplinary AI research teams to develop tailored therapies for our citizens.

Łatwogang raises millions for DMD therapy, while ChatGPT treats cancer for $3,000. Is drug reimbursement a dead end? Read the analysis and the alternative.